AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30866465 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impression group (DIG)
Number of subjects: 50
Study 30866465 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression group (CIG)
Number of subjects: 50
Study 30866465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DIG and CIG)
Number of subjects: 50
Study 28701090 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference Focused Psychotherapy (TFP) combined with group skills training from Dialectic Behavior Therapy (DBT)
Number of subjects: 0
Study 26553085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone (8 mg)
Number of subjects: 172
Study 26553085 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water, 8 mg)
Number of subjects: 172
Study 23934515 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training according to the YIDL system (1-hour group session per day for 1 week, followed by 3 weeks of home practice with audiocassette recordings)
Number of subjects: 32
Study 23934515 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (same for both groups)
Number of subjects: 32
Study 22279697 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal adherence for ordering a lipoprotein profile
Number of subjects: 7745
Study 22279697 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal adherence for pharmacotherapy initiations
Number of subjects: 7745
Study 22279697 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal adherence for drug up-titrations
Number of subjects: 7745
Study 22279697 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal adherence for referrals for specialist consultation
Number of subjects: 7745
Study 22279697 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute adherence for drug up-titrations
Number of subjects: 7745
Study 22279697 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute adherence for referrals for consultation
Number of subjects: 7745
Study 19457255 — intervention group
Group type: EXPERIMENTAL
Intervention: WPS-RA at week 24 for ACR20 responders
Number of subjects: 220
Study 19457255 — intervention group
Group type: EXPERIMENTAL
Intervention: WPS-RA at week 24 for HAQ-DI responders
Number of subjects: 220
Study 19457255 — intervention group
Group type: EXPERIMENTAL
Intervention: WPS-RA at week 24 for non-responders
Number of subjects: 220
Study 19457255 — intervention group
Group type: COMPARATOR
Intervention: WPS-RA for subjects with lower HAQ-DI or SF-36 scores
Number of subjects: 220
Study 19457255 — intervention group
Group type: EXPERIMENTAL
Intervention: WPS-RA for work absenteeism and days with outside help
Number of subjects: 220
Study 16490876 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-microg dose of mometasone furoate nasal spray administered once daily
Number of subjects: 310
Study 16490876 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-microg dose of mometasone furoate nasal spray administered twice daily
Number of subjects: 310
Study 16490876 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo administered in the morning and evening
Number of subjects: 310
Study 15214595 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI floxuridine
Number of subjects: 0
Study 15214595 — intervention group
Group type: COMPARATOR
Intervention: HAI fluorouracil (5-FU)
Number of subjects: 0
Study 15214595 — intervention group
Group type: COMPARATOR
Intervention: Systemically administered 5-FU
Number of subjects: 0
Study 15214595 — intervention group
Group type: COMPARATOR
Intervention: HAI chemotherapy
Number of subjects: 0
Study 11141713 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive management (0.45% saline intravenously, mannitol 20% 250 mL i.v., furosemide 80 mg i.v., dopamine 3 g/Kg/min i.v.)
Number of subjects: 45
Study 11141713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16250725 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment package
Number of subjects: 39
Study 7930276 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day (increased to 10 mg/day after 4 weeks)
Number of subjects: 250
Study 7930276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 2843341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 77
Study 2843341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril + HCTZ
Number of subjects: 77
Study 2843341 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ
Number of subjects: 77
Study 2843341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 77
Study 2843341 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 77
Study 2843341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 77
Study 2843341 — intervention group
Group type: COMPARATOR
Intervention: All other agents
Number of subjects: 77
Study 31635497 — intervention group
Group type: EXPERIMENTAL
Intervention: BCX7353 (oral plasma kallikrein inhibitor), taken as an oral capsule, once daily.
Number of subjects: 0
Study 29231583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint plaster therapy with midnight-noon ebb-flow hour-prescription method
Number of subjects: 76
Study 29231583 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupoint plaster therapy
Number of subjects: 76
Study 25926413 — intervention group
Group type: COMPARATOR
Intervention: Iron-Folic Acid (IFA)
Number of subjects: 869
Study 25926413 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient Mix (MMN)
Number of subjects: 869
Study 25926413 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNS)
Number of subjects: 869
Study 23291612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol extract of Hedyotis diffusa Willd (EEHDW)
Number of subjects: 1
Study 21544006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 111
Study 21544006 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 111
Study 19200622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin plus ibuprofen and oxycodone
Number of subjects: 80
Study 19200622 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen and oxycodone alone
Number of subjects: 80
Study 17405199 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal anaesthesia using EMLA applied transcutaneously 120 minutes prior to the operation (Group A)
Number of subjects: 50
Study 17405199 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration anaesthesia using lidocaine (Group B)
Number of subjects: 50
Study 17405199 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal anaesthesia using EMLA (Group A)
Number of subjects: 50
Study 15572497 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective paper hot flush diary
Number of subjects: 55
Study 15572497 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic event markers
Number of subjects: 55
Study 15572497 — intervention group
Group type: COMPARATOR
Intervention: Biolog ambulatory sternal skin conductance monitor
Number of subjects: 55
Study 10991932 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME, 1 micromol per nostril every 30 min for 6 h
Number of subjects: 0
Study 10991932 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine, 30 micromol
Number of subjects: 0
Study 10991932 — intervention group
Group type: EXPERIMENTAL
Intervention: D-NAME, 1 micromol
Number of subjects: 0
Study 10991932 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA, 1 micromol
Number of subjects: 0
Study 10991932 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF, 60 microg
Number of subjects: 0
Study 10991932 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of L-NAME, 1 micromol
Number of subjects: 0
Study 9082864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 9082864 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 9082864 — intervention group
Group type: COMPARATOR
Intervention: Control (Awake data)
Number of subjects: 30
Study 8349916 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 0
Study 3546155 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin
Number of subjects: 78
Study 3546155 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ofloxacin
Number of subjects: 78
Study 29777864 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based dietary counseling +800 mg/day DHA supplementation
Number of subjects: 1000
Study 29777864 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day DHA
Number of subjects: 1000
Study 29777864 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based dietary counseling +200 mg/day DHA
Number of subjects: 1000
Study 29777864 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day DHA
Number of subjects: 1000
Study 27487082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette cue exposure
Number of subjects: 90
Study 27487082 — intervention group
Group type: COMPARATOR
Intervention: Neutral cue exposure
Number of subjects: 90
Study 24939437 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Tocopherol (400 IU/day)
Number of subjects: 93
Study 24939437 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Lipoic acid (ALA) (100 mg/day)
Number of subjects: 93
Study 24939437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 23010871 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in temperature and humidity associated with enrollment event
Number of subjects: 0
Study 23010871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender, region, and history of stroke
Number of subjects: 0
Study 21992977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV-05 (LACTIN-V) applied vaginally once daily for 5 days, followed by weekly application over 2 weeks
Number of subjects: 24
Study 21992977 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied vaginally once daily for 5 days, followed by weekly application over 2 weeks
Number of subjects: 24
Study 21992977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV-05 (LACTIN-V)
Number of subjects: 24
Study 21992977 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous L. crispatus presence
Number of subjects: 24
Study 21992977 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal intercourse during the study
Number of subjects: 24
Study 18507266 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 59
Study 18507266 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 59
Study 16403712 — intervention group
Group type: EXPERIMENTAL
Intervention: CorX system (group A)
Number of subjects: 81
Study 16403712 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB system (group B)
Number of subjects: 81
Study 14634680 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐OB protein (80 mg) administered subcutaneously weekly for 6 weeks
Number of subjects: 24
Study 14634680 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously weekly for 6 weeks
Number of subjects: 24
Study 14634680 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐OB protein (80 mg)
Number of subjects: 24
Study 14634680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10718694 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based physical activity counseling
Number of subjects: 0
Study 10718694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions with written materials
Number of subjects: 0
Study 10718694 — intervention group
Group type: COMPARATOR
Intervention: Primary care-based physical activity interventions
Number of subjects: 0
Study 8877657 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun/Oral-B Plak Control)
Number of subjects: 20
Study 8877657 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 20
Study 8877657 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Rotadent)
Number of subjects: 20
Study 8877657 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Interplak)
Number of subjects: 20
Study 8877657 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun)
Number of subjects: 20
Study 8877657 — intervention group
Group type: EXPERIMENTAL
Intervention: All toothbrushes
Number of subjects: 20
Study 1713999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary gallopamil 3.0 micrograms/kg
Number of subjects: 14
Study 1713999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary gallopamil 1.5 micrograms/kg
Number of subjects: 14
Study 1713999 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary saline
Number of subjects: 14
Study 6109119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry artificial lung surfactant (one dose)
Number of subjects: 22
Study 6109119 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 subjects)
Number of subjects: 22
Study 30649276 — intervention group
Group type: EXPERIMENTAL
Intervention: CFA (Complex Fractionated Atrial Electrogram-guided Focal Ablation)
Number of subjects: 150
Study 30649276 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (CFAE-guided Linear Ablation)
Number of subjects: 150
Study 30649276 — intervention group
Group type: EXPERIMENTAL
Intervention: CFA
Number of subjects: 150
Study 30649276 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA
Number of subjects: 150
Study 28633874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry (DXA)
Number of subjects: 48
Study 28633874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 48
Study 26370443 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mcg misoprostol
Number of subjects: 748
Study 26370443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748
Study 23469256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-300 mg BID)
Number of subjects: 64
Study 23469256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21441812 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) alone
Number of subjects: 2
Study 21441812 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) in combination with a probiotic
Number of subjects: 2
Study 21441812 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 20925776 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium prevention protocol implemented on intervention unit patients
Number of subjects: 70
Study 20925776 — intervention group
Group type: COMPARATOR
Intervention: Usual care without delirium protocol
Number of subjects: 70
Study 17407458 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-odour condition
Number of subjects: 13
Study 17407458 — intervention group
Group type: COMPARATOR
Intervention: Water-control condition
Number of subjects: 13
Study 15234488 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made insoles
Number of subjects: 20
Study 15234488 — intervention group
Group type: COMPARATOR
Intervention: Flat insoles
Number of subjects: 20
Study 15513446 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG) combined with feeder vessel treatment (FVT)
Number of subjects: 0
Study 15513446 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG)
Number of subjects: 0
Study 9467516 — intervention group
Group type: EXPERIMENTAL
Intervention: Stresst'er ergometer
Number of subjects: 94
Study 9467516 — intervention group
Group type: COMPARATOR
Intervention: Treadmill testing
Number of subjects: 94
Study 7941947 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) insertion
Number of subjects: 40
Study 7941947 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscopy and Tracheal Intubation
Number of subjects: 40
Study 3328285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (S)
Number of subjects: 230
Study 3328285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate + Cimetidine (S + C)
Number of subjects: 230
Study 3328285 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (C)
Number of subjects: 230
Study 31773734 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS-C)
Number of subjects: 176
Study 31773734 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation about sleep and health (PE)
Number of subjects: 176
Study 30098269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 47
Study 30098269 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 47
Study 28271568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziziphus jujube fruit (ZJF) infusion (10 g/100 mL boiling water) three times/day before main meals for 12 weeks
Number of subjects: 116
Study 28271568 — intervention group
Group type: COMPARATOR
Intervention: Balanced diet
Number of subjects: 116
Study 26180244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-based meal
Number of subjects: 16
Study 26180244 — intervention group
Group type: COMPARATOR
Intervention: Soy oil-based meal
Number of subjects: 16
Study 24124681 — intervention group
Group type: EXPERIMENTAL
Intervention: HPP group (hemi-portal vein preserved inflow occlusion)
Number of subjects: 180
Study 24124681 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV group (main portal vein inflow occlusion)
Number of subjects: 180
Study 24124681 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV group (hemi-hepatic vascular inflow occlusion)
Number of subjects: 180
Study 24124681 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV group
Number of subjects: 180
Study 24124681 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV group
Number of subjects: 180
Study 20528210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol-drospirenone
Number of subjects: 41
Study 20528210 — intervention group
Group type: COMPARATOR
Intervention: Flutamide-metformin
Number of subjects: 41
Study 20528210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with ethinylestradiol-drospirenone and flutamide-metformin
Number of subjects: 41
Study 18931625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT) - fixed 8‐week off, 8‐week on regimen
Number of subjects: 403
Study 18931625 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment (CT) - maintain current treatment strategy
Number of subjects: 403
Study 18931625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT)
Number of subjects: 403
Study 18931625 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment (CT)
Number of subjects: 403
Study 16820341 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA (140 mg/day) from green coffee bean extract
Number of subjects: 28
Study 16820341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14968473 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of elemental zinc for 3 months
Number of subjects: 25
Study 14968473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10979549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 8968239 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 437
Study 8968239 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 437
Study 8968239 — intervention group
Group type: COMPARATOR
Intervention: Medical management of miscarriage
Number of subjects: 437
Study 1590494 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused cognitive therapy for 12 weeks
Number of subjects: 33
Study 1590494 — intervention group
Group type: COMPARATOR
Intervention: Brief supportive psychotherapy for 8 weeks (Control)
Number of subjects: 33
Study 1590494 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to focused cognitive therapy for 12 weeks
Number of subjects: 33
Study 6084394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylpropanolamine (PPA) solution
Number of subjects: 40
Study 6084394 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 40
Study 30630581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 108
Study 30630581 — intervention group
Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 108
Study 28841508 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Control & Strengthening group (MC&S group)
Number of subjects: 34
Study 28841508 — intervention group
Group type: COMPARATOR
Intervention: Strengthening group (S group)
Number of subjects: 34
Study 26515839 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly targeted ultraviolet B phototherapy
Number of subjects: 60
Study 26515839 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly targeted ultraviolet B phototherapy
Number of subjects: 60
Study 24229746 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (flexible dose 5-20 mg/d, all reaching 20 mg/d)
Number of subjects: 31
Study 24229746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24229746 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 31
Study 21557134 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed, targeted materials
Number of subjects: 0
Study 21557134 — intervention group
Group type: COMPARATOR
Intervention: Standard care materials (control)
Number of subjects: 0
Study 19477434 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential avoidance (EA)
Number of subjects: 81
Study 19477434 — intervention group
Group type: COMPARATOR
Intervention: Depression
Number of subjects: 81
Study 17060222 — intervention group
Group type: EXPERIMENTAL
Intervention: Visited group (systematic on-site visits)
Number of subjects: 69
Study 17060222 — intervention group
Group type: COMPARATOR
Intervention: Non-visited group (no systematic on-site visits)
Number of subjects: 69
Study 17060222 — intervention group
Group type: EXPERIMENTAL
Intervention: Visited group
Number of subjects: 69